MX2020002406A - Anticuerpo anti-epha4. - Google Patents
Anticuerpo anti-epha4.Info
- Publication number
- MX2020002406A MX2020002406A MX2020002406A MX2020002406A MX2020002406A MX 2020002406 A MX2020002406 A MX 2020002406A MX 2020002406 A MX2020002406 A MX 2020002406A MX 2020002406 A MX2020002406 A MX 2020002406A MX 2020002406 A MX2020002406 A MX 2020002406A
- Authority
- MX
- Mexico
- Prior art keywords
- epha4
- antibody
- binding
- mouse anti
- epha4 antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se pretende proporcionar un anticuerpo anti-EphA4 o un fragmento de unión a EphA4 del mismo que sea capaz de unirse a EphA4 e inhibir la unión entre EphA4 y su ligando, y una composición farmacéutica que comprende el anticuerpo anti-EphA4 o el fragmento de unión a EphA4 del mismo como un ingrediente activo. Se obtuvo un anticuerpo anti-EphA4 de ratón que tiene afinidad de unión por EphA4, y se identificaron las secuencias de regiones determinantes de complementariedad (CDR) del anticuerpo anti-EphA4 de ratón. Esto permitió la preparación de un anticuerpo humanizado que comprende las secuencias de CDR del anticuerpo anti-EphA4 de ratón en la región variable de la cadena pesada y la región 15 variable de la cadena ligera.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015177081 | 2015-09-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020002406A true MX2020002406A (es) | 2020-07-22 |
Family
ID=58240770
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018002164A MX2018002164A (es) | 2015-09-08 | 2016-09-06 | Anticerpo anti-epha4. |
| MX2020002406A MX2020002406A (es) | 2015-09-08 | 2018-02-20 | Anticuerpo anti-epha4. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018002164A MX2018002164A (es) | 2015-09-08 | 2016-09-06 | Anticerpo anti-epha4. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US10428140B2 (es) |
| EP (1) | EP3381941B1 (es) |
| JP (2) | JP6738814B2 (es) |
| KR (1) | KR20180041136A (es) |
| CN (2) | CN107922499B (es) |
| AR (1) | AR105938A1 (es) |
| AU (1) | AU2016319433A1 (es) |
| BR (1) | BR112018003494A2 (es) |
| CA (1) | CA2989993A1 (es) |
| CO (1) | CO2018000652A2 (es) |
| ES (1) | ES2846175T3 (es) |
| IL (2) | IL256519A (es) |
| MX (2) | MX2018002164A (es) |
| PE (1) | PE20181051A1 (es) |
| PH (1) | PH12018500290A1 (es) |
| RU (2) | RU2019128192A (es) |
| SG (1) | SG11201800127WA (es) |
| TW (1) | TW201716442A (es) |
| WO (1) | WO2017043466A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3936607A4 (en) * | 2019-03-08 | 2023-01-04 | Kaneka Corporation | MASS CULTURE OF PLURIPOTENTS STEM CELLS |
| TW202342101A (zh) * | 2019-07-01 | 2023-11-01 | 日商衛材R&D企管股份有限公司 | 抗EphA4抗體 |
| CA3195085A1 (en) | 2020-12-24 | 2022-06-30 | Eisai R&D Management Co., Ltd. | Therapeutic pharmaceutical composition for amyotrophic lateral sclerosis |
| CA3192342A1 (en) * | 2020-12-24 | 2022-06-30 | Eisai R&D Management Co., Ltd. | Anti-epha4 antibody |
| TW202323286A (zh) * | 2021-11-11 | 2023-06-16 | 日商衛材R&D企管股份有限公司 | 抗EphA4抗體 |
| CN118696063A (zh) * | 2021-11-22 | 2024-09-24 | 洪明奇 | Ephrin a型受体10特异性抗体、包含其之融合蛋白、表现其之嵌合抗原受体t细胞及其应用 |
| WO2023122647A2 (en) * | 2021-12-22 | 2023-06-29 | The University Of Chicago | Methods for detecting or treating influenza infections |
| WO2024047558A2 (en) * | 2022-08-31 | 2024-03-07 | Immuneel Therapeutics Private Limited | Antigen-binding proteins and chimeric antigen receptors specific for domain 9 of human cd307e |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4334271B2 (ja) * | 2003-05-07 | 2009-09-30 | セレスター・レキシコ・サイエンシズ株式会社 | 抗体配列作成装置、抗体配列作成方法、プログラム、および、記録媒体 |
| WO2005048917A2 (en) * | 2003-06-06 | 2005-06-02 | Medimmune, Inc. | Use of epha4 and modulator or epha4 for diagnosis, treatment and prevention of cancer |
| ATE501173T1 (de) * | 2003-12-04 | 2011-03-15 | Abbott Biotherapeutics Corp | Anti-ip-10-antikörper |
| EP1733047A2 (en) * | 2004-02-27 | 2006-12-20 | Oncotherapy Science, Inc. | Pin-prc transition genes |
| US20080008719A1 (en) * | 2004-07-10 | 2008-01-10 | Bowdish Katherine S | Methods and compositions for the treatment of prostate cancer |
| EP1662259A1 (en) * | 2004-11-25 | 2006-05-31 | Cellzome Ag | Use of Eph receptor inhibitors for the treatment of neurodegenerative diseases |
| CN101432022A (zh) | 2006-02-28 | 2009-05-13 | 肿瘤疗法科学股份有限公司 | 利用抗-EphA4抗体效应物作用损伤细胞的方法 |
| US7910324B2 (en) | 2007-06-08 | 2011-03-22 | Eisai R&D Management Co., Ltd. | Method of screening for compounds which affect the processing of EphA4 by γ-secretase |
| US7892769B2 (en) * | 2007-11-30 | 2011-02-22 | Eisai R&D Management Co., Ltd. | Processing of EphA4 polypeptide by γ-secretase activity |
| JP2010285413A (ja) * | 2009-06-10 | 2010-12-24 | Univ Of Melbourne | 治療用途 |
| WO2010141974A1 (en) | 2009-06-10 | 2010-12-16 | The University Of Melbourne | Therapeutic applications |
| EP2486058A1 (en) * | 2009-10-09 | 2012-08-15 | Sanofi | Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same |
| DK2653552T3 (en) | 2010-12-17 | 2017-01-16 | Eisai R&D Man Co Ltd | SCREENING METHOD USING GELATINASE-MEDIATED EphA4 DIVISION REACTION AS INDICATOR |
| JP5961608B2 (ja) * | 2011-04-25 | 2016-08-02 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ＥｐｈＡ４細胞外ドメインの測定による認知機能障害を伴う神経系疾患の検出方法 |
| GB201107996D0 (en) | 2011-05-13 | 2011-06-29 | Vib Vzw | EphA4 is a diease modifier in motor neuron disease |
| JP6811706B2 (ja) * | 2014-07-31 | 2021-01-13 | ザ ホンコン ユニヴァーシティ オブ サイエンス アンド テクノロジー | Ｅｐｈａ４に対するヒトモノクローナル抗体及びそれらの使用 |
-
2016
- 2016-09-06 RU RU2019128192A patent/RU2019128192A/ru unknown
- 2016-09-06 EP EP16844327.3A patent/EP3381941B1/en active Active
- 2016-09-06 KR KR1020187004754A patent/KR20180041136A/ko unknown
- 2016-09-06 AR ARP160102725A patent/AR105938A1/es unknown
- 2016-09-06 CN CN201680048438.4A patent/CN107922499B/zh active Active
- 2016-09-06 SG SG11201800127WA patent/SG11201800127WA/en unknown
- 2016-09-06 AU AU2016319433A patent/AU2016319433A1/en not_active Abandoned
- 2016-09-06 CN CN202010179415.5A patent/CN111320693B/zh active Active
- 2016-09-06 US US15/753,611 patent/US10428140B2/en active Active
- 2016-09-06 RU RU2018106456A patent/RU2719158C2/ru active
- 2016-09-06 JP JP2017539163A patent/JP6738814B2/ja active Active
- 2016-09-06 CA CA2989993A patent/CA2989993A1/en not_active Abandoned
- 2016-09-06 MX MX2018002164A patent/MX2018002164A/es unknown
- 2016-09-06 ES ES16844327T patent/ES2846175T3/es active Active
- 2016-09-06 PE PE2017002724A patent/PE20181051A1/es not_active Application Discontinuation
- 2016-09-06 WO PCT/JP2016/076102 patent/WO2017043466A1/ja active Application Filing
- 2016-09-06 TW TW105128767A patent/TW201716442A/zh unknown
- 2016-09-06 BR BR112018003494-0A patent/BR112018003494A2/pt not_active Application Discontinuation
-
2017
- 2017-12-24 IL IL256519A patent/IL256519A/en unknown
-
2018
- 2018-01-24 CO CONC2018/0000652A patent/CO2018000652A2/es unknown
- 2018-02-08 PH PH12018500290A patent/PH12018500290A1/en unknown
- 2018-02-20 MX MX2020002406A patent/MX2020002406A/es unknown
-
2019
- 2019-08-23 JP JP2019152823A patent/JP6770153B2/ja active Active
- 2019-08-25 IL IL26888919A patent/IL268889A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020002406A (es) | Anticuerpo anti-epha4. | |
| MX2019005426A (es) | Anticuerpos anti-lag3 y fragmentos de union a antigeno. | |
| MX2022011002A (es) | Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos. | |
| PH12018502225A1 (en) | Anti-il-33 antibodies, compositions, methods and uses thereof | |
| PH12018500707A1 (en) | Anti-human cd19 antibodies with high affinity | |
| MX2018007406A (es) | Anticuerpos anti-lag3 y fragmentos de enlace al antigeno. | |
| MX2020010530A (es) | Anticuerpos humanizados contra cd269 (bcma). | |
| NZ738008A (en) | Tigit-binding agents and uses thereof | |
| EA201890834A1 (ru) | Агонистические антитела, специфически связывающие человеческий cd40, и способы их применения | |
| MX2017012615A (es) | Anticuerpo anti-notch4 humano. | |
| EP4249515A3 (en) | Humanized or chimeric cd3 antibodies | |
| NZ728688A (en) | Anti-pd-1 antibodies | |
| JOP20160131B1 (ar) | الأجسام المضادة للعامل xi وطرق الاستخدام | |
| SG10201901057UA (en) | Anti-pd-l1 antibodies | |
| MX2016012124A (es) | Anticuerpos contra glicopeptidos inmunogenicos, composicion que los comprende y usos de estos. | |
| MX2016007212A (es) | Anticuerpos dirigidos contra la toxina lukgh (lukab) de staphylococcus aureus y secuencias de anticuerpos. | |
| MX2019009498A (es) | Anticuerpos mimeticos de fgf21 y usos de los mismos. | |
| TW201613977A (en) | Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use | |
| EA201992315A1 (ru) | Композиции и способы для лечения рака легкого | |
| NZ736863A (en) | Methods of mediating cytokine expression with anti ccr4 antibodies | |
| EP4218817A3 (en) | Methods for treating metabolic diseases by inhibiting myostatin activation | |
| MX2016014726A (es) | Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1. | |
| MX2022000317A (es) | Anticuerpos altamente potentes que se unen al receptor de muerte 4 y al receptor de muerte 5. |